October/November #175 : Going Norvir-Free? - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents



From the Editor

Retiring the Ribbon


Letters- October/November 2011


High-Impact Prevention

What You Need to Know

Health Care Should Be a Human Right—for All

Too Few Pharma Companies in the Patent Pool

Legislation Proposed to End Criminal HIV Laws

AIDS Is Not an "Automatic Death Sentence"

Geckos Don’t Cure AIDS

We Hear You

The PrEP Debate

What Matters to You

Getting HIV Care Without Getting Deported

Treatment News

A Peek Into the Pipeline

Savvy Survival Strategy

Going Norvir-Free?

Cure Watch

Listen Up

Oh Baby!

Make Some Bones About It

Comfort Zone

Waiting to Inhale

POZ Heroes

Defying Gravity

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

October / November 2011

Going Norvir-Free?

by Laura Whitehorn

To work most effectively, protease inhibitors (PIs) have long relied on a boost from Norvir (ritonavir).

For years, Norvir has been the only PI booster available. A new one, cobicistat, could win FDA approval next year, offering Norvir-takers another choice. In anticipation of the drug’s approval, a fixed dose, single pill combination of Prezista (darunavir) with a cobicistat boost is being tested.

If that works, we could see two new all-in-one quadruple pills—each a complete HIV regimen in one swallow—on pharmacy  shelves. One quad will combine Prezista with cobicistat, Emtriva (emtricita-bine) and GS 7340 (an experimental drug similar to Viread/tenofovir, but possibly more powerful and longer lasting). The other quad will combine cobicistat with elvitegravir (an experimental integrase inhibitor), Emtriva and Viread. For more details on this new med, search “cobicistat” on poz.com.

Another all-in-one is already available: Complera (Edurant/rilpivirine plus Viread plus Emtriva) is approved for people starting their first HIV regimen.

Search: protease inhibitor, PI, Norvir, cobicistat, Prezista, Emtriva, Viread, Complera

Scroll down to comment on this story.

email print


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.